Literature DB >> 21660493

Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients.

Riccardo Polosa1, Mario Malerba, Rossella R Cacciola, Jaymin B Morjaria, Cinzia Maugeri, Gaetano Prosperini, Raimondo Gullo, Lucia Spicuzza, Alessandro Radaeli, Giuseppe U Di Maria.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) are prone to clinical exacerbations that are associated with increased airway inflammation, a potent pro-thrombotic stimulus. Limited information is available on the mechanisms underlying the putative alterations of the endothelial-coagulative system during acute exacerbations. The aim was to investigate whether the activation of the endothelial-coagulative system occurs in association with the acute inflammatory response of COPD exacerbation. We monitored the blood levels of surrogate markers of inflammation: interleukin-6 (IL-6); endothelium damage: von Willebrand's factor (vWF); clotting activation: D-dimer (D-D), and prothrombin fragment 1+2 (F1+2); fibrinolytic response: plasminogen activator inhibitor 1 (PAI-1), in COPD subjects, during hospital admission and after clinical resolution. In 30 COPD subjects, IL-6, vWF, D-D and F1+2 levels were elevated during exacerbation and decreased significantly at clinical stability (IL-6, p = 0.005; vWF, p < 0.001; D-D, p < 0.001; F1+2, p < 0.001). PAI-1 levels did not change at exacerbation compared to clinically stable situations. Positive correlations were observed between several of the markers measured. Elevation of IL-6, vWF, D-D and F1+2 levels during COPD exacerbations implies a strict association between acute inflammation, endothelial activation and clotting initiation. This was not associated with a change in PAI-1, implying an increase in the fibrinolytic response to inflammation. The pro-thrombotic nature of COPD exacerbations sustained by enhanced clotting activation appears to be mitigated by excessive fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660493     DOI: 10.1007/s11739-011-0636-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  39 in total

1.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.

Authors:  L Davies; R M Angus; P M Calverley
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

2.  [Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations].

Authors:  D Mispelaere; J C Glerant; M Audebert; A Remond; M A Sevestre-Pietri; V Jounieaux
Journal:  Rev Mal Respir       Date:  2002-09       Impact factor: 0.622

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.

Authors:  A Rumley; G D Lowe; P M Sweetnam; J W Yarnell; R P Ford
Journal:  Br J Haematol       Date:  1999-04       Impact factor: 6.998

5.  The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function.

Authors:  S Ogawa; R Shreeniwas; J Brett; M Clauss; M Furie; D M Stern
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

6.  Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease?

Authors:  Olivier T Rutschmann; Jacques Cornuz; Pierre-Alexandre Poletti; Pierre-Olivier Bridevaux; Olivier W Hugli; Salah D Qanadli; Arnaud Perrier
Journal:  Thorax       Date:  2006-11-13       Impact factor: 9.139

7.  Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.

Authors:  C Alessandri; S Basili; F Violi; P Ferroni; P P Gazzaniga; C Cordova
Journal:  Thromb Haemost       Date:  1994-09       Impact factor: 5.249

8.  Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals.

Authors:  A D Blann; C N McCollum; G Y Lip
Journal:  Blood Coagul Fibrinolysis       Date:  2002-09       Impact factor: 1.276

Review 9.  Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD.

Authors:  Marco Ambrosetti; Walter Ageno; Antonio Spanevello; Mario Salerno; Roberto F E Pedretti
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

Review 10.  Pharmacological treatment of chronic obstructive pulmonary disease.

Authors:  Paolo Montuschi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more
  13 in total

Review 1.  Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.

Authors:  Hammad Qureshi; Amir Sharafkhaneh; Nicola A Hanania
Journal:  Ther Adv Chronic Dis       Date:  2014-09       Impact factor: 5.091

2.  Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum.

Authors:  Stefan Röpcke; Olaf Holz; Gereon Lauer; Meike Müller; Susanne Rittinghausen; Peter Ernst; Gezim Lahu; Martin Elmlinger; Norbert Krug; Jens M Hohlfeld
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

Review 3.  The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD).

Authors:  Clara E Green; Alice M Turner
Journal:  Respir Res       Date:  2017-01-18

4.  The association of elevated circulating endocan levels with lung function decline in COPD patients.

Authors:  Luqi Dai; Junyun He; Jun Chen; Tao Wang; Lian Liu; Yongchun Shen; Lei Chen; Fuqiang Wen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-09

5.  Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers.

Authors:  Qiuying Chen; Ruba S Deeb; Yuliang Ma; Michelle R Staudt; Ronald G Crystal; Steven S Gross
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

Review 6.  Stroke risk among patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Authors:  Yu Ree Kim; In Cheol Hwang; Yong Joo Lee; Eun Bee Ham; Dong Kyun Park; Sewan Kim
Journal:  Clinics (Sao Paulo)       Date:  2018-05-03       Impact factor: 2.365

7.  Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort.

Authors:  Sarah R Rønnow; Lasse L Langholm; Morten A Karsdal; Tina Manon-Jensen; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; Diana J Leeming; Jannie M B Sand
Journal:  Respir Res       Date:  2020-07-30

8.  Long-Term Outcomes in Patients with Incident Chronic Obstructive Pulmonary Disease after Acute Kidney Injury: A Competing-Risk Analysis of a Nationwide Cohort.

Authors:  Che-Hsiung Wu; Huang-Ming Chang; Cheng-Yi Wang; Likwang Chen; Liang-Wen Chen; Chien-Heng Lai; Shuenn-Wen Kuo; Hao-Chien Wang; Vin-Cent Wu
Journal:  J Clin Med       Date:  2018-08-24       Impact factor: 4.241

9.  Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk.

Authors:  Lasse L Langholm; Sarah Rank Rønnow; Jannie M B Sand; Diana Julie Leeming; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; Morten A Karsdal; Tina Manon-Jensen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-09

Review 10.  Sleep Deprivation, Immune Suppression and SARS-CoV-2 Infection.

Authors:  Beatrice Ragnoli; Patrizia Pochetti; Patrizia Pignatti; Mariangela Barbieri; Lucrezia Mondini; Luca Ruggero; Liliana Trotta; Paolo Montuschi; Mario Malerba
Journal:  Int J Environ Res Public Health       Date:  2022-01-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.